The increases in ERK1/2 and Akt phosphorylation that we observed were not inhibited by PDGFR inhibitors but were inhibited by an EGFR inhibitor, despite SSc IgG binding to PDGFR-β. This evidence concerns the gene MAPK3 and systemic sclerosis.